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Background: Few studies have examined the protein binding ratio of levofloxacin (LVFX) in patients undergoing
hemodialysis (HD).
Methods: We evaluated the serum concentration and protein binding ratio of LVFX in HD patients. Subjects
were 13 patients (7 non-HD and 6 HD patients) undergoing LVFX therapy for pneumonia, urinary tract infection,
osteomyelitis, and unidentified infections from June 2012 to December 2013. To clarify the relationship between
protein concentration and the protein binding ratio of LVFX in vitro and in vivo, the effect of human albumin and
globulin on the binding ratio was investigated.
Results: The protein binding ratio of LVFX was 31.2 and 29.3 % in non-HD and HD patients, respectively. A statistically
significant correlation was observed between the serum albumin level and protein binding ratio in vivo. LVFX was
bound to not only albumin but also globulin; further, in vitro, the protein binding ratio of LVFX increased with an
increase in the albumin or globulin concentration. However, the protein binding ratio did not increase with increased
serum globulin concentrations in the presence of 3.5 g/dL albumin.
Conclusions: The protein binding ratio of LVFX has little clinical relevance, and it is not necessary to monitor it for
LVFX therapy in HD patients.
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Levofloxacin (LVFX) belongs to the fluoroquinolone
class of antimicrobial agents, with broad-spectrum activ-
ity against Gram-positive and Gram-negative bacteria,
including Pseudomonas aeruginosa [1]. Because of its
clinical and bacteriological efficacy, LVFX is an import-
ant antimicrobial drug for treating serious infections [2].
LVFX is excreted primarily unchanged by the kidneys
(79.6 %) [1]. Its elimination half-life ranges from 4.3 to
8.9 h in individuals with normal renal function [1] and
from 18.4 to 43.5 h in hemodialysis (HD) patients [3].
The serum protein binding ratio of LVFX is approxi-
mately 24–38 %, and it is mainly bound to serum albu-
min in humans [1]. The 24-h area under the curve/
minimum inhibitory concentration (AUC24/MIC) ratio
correlates with the efficacy of fluoroquinolones [4]. An
AUC24/MIC ratio of 125 is correlated with optimal* Correspondence: ccrtyo34057@gmail.com
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patients infected with Gram-negative bacteria [5], while
a free-drug AUC24/MIC ratio >33.7 has been associated
with 100 % microbiological response in respiratory tract
infections caused by Streptococcus pneumoniae [6]. Pro-
tein binding of fluoroquinolones has been considered to
be of uncertain clinical relevance. It appears more desir-
able to have high levels of freely available drug so that it
is clinically active than to have a large proportion of
bound and potentially inactive drug [7]. In vitro exami-
nations have demonstrated that protein binding leads to
a significant reduction in the antimicrobial activity of
moxifloxacin and trovafloxacin [8, 9]. Scaglione et al.
[10] reported that the unbound fraction (67–88 %) was
concentration dependent for LVFX and ciprofloxacin
(0.5–80 mg/L) in a murine pneumonia model and that
protein binding may affect the pharmacodynamics of
fluoroquinolones.
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failure, advanced age, inflammatory diseases, and cancers
[7]. We hypothesized that in HD patients, the protein
binding ratio of LVFX would fluctuate widely, potentially
affecting antimicrobial activity. However, little informa-
tion is available regarding the protein binding ratio of
LVFX in HD patients. Therefore, this study aimed to
evaluate the serum concentration and protein binding
ratio of LVFX in HD patients.
Methods
Materials
LVFX and pazufloxacin (PZFX) were provided by Daiichi
Sankyo Co., Ltd. (Tokyo, Japan) and Taisho-Toyama
Pharmaceuticals Co., Ltd. (Tokyo, Japan), respectively.
Oasis HLB 1-cm3 (30-mg) extraction cartridges were ob-
tained commercially from Waters Corporation (Milford,
MA). Human albumin and globulin were purchased
from Wako Pure Chemical Industries (Osaka, Japan). All
other chemicals were of analytical grade and commer-
cially available.
Subjects
Clinical laboratory data were collected from 13 patients,
including 7 non-HD patients and 6 HD patients, who
were undergoing LVFX therapy for pneumonia, urinary
tract infection, osteomyelitis, and unidentified infections
from June 2012 to December 2013. Non-HD patients re-
ceived LVFX 500 mg once daily orally, and HD patients
received LVFX 500 mg initially, followed by 250 mg after
each HD session orally. All subjects were administered
LVFX therapy for 4–48 days. HD patients underwent
thrice-weekly HD in the LVFX treatment period. Writ-
ten informed consent was obtained from all subjects be-
fore enrollment in this study. This study and its protocol
were approved by the Ethics Committee of Kaetsu
Hospital.
Blood sampling
To determine the serum concentration of LVFX and to
obtain other laboratory data, blood samples were ob-
tained just before HD and on non-HD days in HD pa-
tients and just before LVFX administration and 12 h
after administration in non-HD patients. Blood sampling
times were different in order to obtain appropriate clin-
ical blood samples to evaluate infectious diseases. Blood
samples were obtained 2–18 days after the administra-
tion of LVFX was initiated. Both total and free fraction
concentrations of LVFX were measured in the 13 pa-
tients to determine the correlations between serum albu-
min, serum globulin, serum concentration of LVFX, and
protein binding ratio of LVFX. To clarify the relationship
between protein concentration and the protein binding
ratio of LVFX in vitro and in vivo, the effect of humanalbumin and globulin on the protein binding ratio of
LVFX in phosphate buffer (pH 7.4) was investigated.Preparation of sample solutions
To determine the relationship between the serum con-
centration (1, 2, 4, 8, 10, and 20 mg/L as the general
serum concentration and 50 and 100 mg/L as the high
serum concentration) and the protein binding ratio of
LVFX in vitro, the effect of the protein binding ratio was
investigated using 0.025 M phosphate buffer solution
(pH 7.5). To determine the relationship between the
protein concentration and the protein binding ratio of
LVFX in vitro, the effect of human albumin and globulin
on the binding ratio was investigated using 0.025 M
phosphate buffer solution (pH 7.5). After the samples
were incubated for 30 min at 37 °C, the free fraction of
the samples was obtained by ultrafiltration (molecular
weight cutoff, 10,000 Da).Assay
Serum LVFX concentrations were determined by HPLC
using PZFX as the internal standard (IS). Briefly, sample
processing was performed using a solid phase extraction
cartridge. The cartridges were conditioned with methanol
and water. After the sample (100 μL serum sample +
100 μL IS + 900 μL 0.025 M phosphate buffer solution;
pH 7.5) was loaded, the cartridge was washed with 1 mL
of 5 % methanol in water. The sample was eluted with
1 mL of mobile phase, and 50 μL was injected onto the
HPLC column for analysis. The HPLC system consisted of
a reverse-phase column (Shim-pack, CLC-CN, Shimadzu
Corp., Kyoto, Japan), and the fluorescence of the mobile
phase was monitored (excitation wavelength, 278 nm;
emission wavelength, 445 nm). The mobile phase con-
sisted of a mixture (pH 3.0) of phosphate buffer, aceto-
nitrile, and triethylamine (171:29:1 by volume), and the
flow rate was 1.0 mL/min. The retention times of the IS
and LVFX were 6.0 and 6.8 min, respectively. The lower
limit of quantification of this system was 0.05 μg/mL
in 0.1 mL of serum. Inter- and intra-day variations
were <5.0 %. The free fractions of the serum and
spiked samples were obtained by ultrafiltration using a
disposable ultrafilter (Kurabo Industries, Ltd., Osaka,
Japan). The protein binding ratio of LVFX was calculated
from the total and free concentration of LVFX.Statistical analysis
Data are expressed as mean ± standard deviation. Statis-
tical analysis was performed using the Student’s t test or
Pearson’s correlation coefficient test, and significance
was set at p < 0.05. JMP 9 Software (SAS Institute Inc.,
Cary, NC) was used for all statistical analyses.
Table 1 Patient profiles and serum concentration and protein






Age (years) 80.9 ± 12.1 75.3 ± 15.3 0.48
Sex (female/male) 6/1 0/6 –
Body weight (kg) 44.5 ± 12.2 – –
Dry weight (kg) – 60.6 ± 18.4 0.09
Serum creatinine (mg/dL) 0.7 ± 0.3 8.9 ± 3.9 <0.05
Total protein (g/dL) 6.3 ± 0.4 6.2 ± 0.7 0.63
Albumin (g/dL) 3.1 ± 0.4 3.4 ± 0.5 0.35
Serum concentration of
LVFX (mg/L)
4.5 ± 2.6 5.2 ± 2.3 0.62
Protein binding ratio of LVFX (%) 31.2 ± 5.3 29.3 ± 6.4 0.55
Values represent means ± standard deviation
HD hemodialysis, LVFX levofloxacin
aThe statistical difference was determined by Student’s t test for non-HD patients
vs. HD patients. Statistical analysis of weight involving total body weight
in non-HD patients vs. dry weight in HD patients
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Patient profiles, serum concentrations, and protein bind-
ing ratios of LVFX are shown in Table 1. For HD pa-
tients, demographic profiles, HD backgrounds, LVFX
concentrations, and protein binding ratios are shown in
Table 2. Serum globulin was not measured in one pa-
tient. For non-HD patients, the demographic profiles,
backgrounds, LVFX concentrations, and protein binding
ratios are shown in Table 3. Serum globulin was not
measured in all patients. In HD patients, serum LVFX
concentrations and protein binding ratio were 4.3 ±
2.2 mg/dL and 27.3 ± 6.6 % just before HD (n = 4)
and 7.1 ± 0.8 mg/dL and 33.2 ± 5.1 % on non-HD days




Sex DW (kg) SAr (m2) DM BFR (mL/min) TT (h)
1 52 Male 96.0 2.2 PS 250 5
2 88 Male 48.7 0.9 CTA 160 3
3 82 Male 51.5 1.1 PES 160 4
4 62 Male 64.0 1.9 PES 220 4
5 91 Male 47.5 1.1 PES 180 4
6 77 Male 55.8 1.9 PES 200 4
Average 75.3 60.6 1.5 195.0 4.0
SD 15.3 18.4 0.5 35.6 0.6
SD standard deviation, DW dry weight, SAr surface area, DM dialyzer membrane, BF
administration of levofloxacin, SP serum protein, SA serum albumin, SG serum globu
HD hemodialysis, PS polysulfone, CTA cellulose triacetate, PES polyether sulfoneconcentrations and protein binding ratio were 3.7 ±
2.7 mg/dL and 33.4 ± 4.7 % just before the administration
of LVFX (n = 5) and 6.6 ± 1.2 mg/dL and 25.9 ± 1.6 % on
12 h after the administration of LVFX (n = 2), respectively.
The relationship between the serum albumin con-
centration and protein binding ratio of LVFX in HD
(p = 0.16, r = 0.66) and non-HD patients (p = 0.05, r =
0.75) is shown in Fig. 1, wherein a statistically signifi-
cant (p = 0.03) correlation (r = 0.60) was observed in
all the patients. Among the oral medications taken by
the patients, those known to have interactions with
LVFX administered concurrently in HD patients were
as follows: iron agents 50 mg taken by patient no. 3,
lanthanum carbonate hydrate 750 mg and sevelamer
hydrochloride 1500 mg taken by patient no. 4, and
calcium carbonate 500 mg taken by patient no. 6.
The oral medication known to have interactions with
LVFX administered concurrently in non-HD patients
was magnesium oxide 250 mg taken by patient no. 3.
In contrast, the relationship between the serum con-
centration and protein binding ratio of LVFX in patients
showed no statistically significant (p = 0.96) correlation
(r = 0.02). In vitro, the relationship between the serum
concentration and protein binding ratio of LVFX in
human serum, as observed in Fig. 2, showed no statisti-
cally significant (p = 0.91) correlation (r = 0.03). The rela-
tionship between the serum albumin concentration and
protein binding ratio of LVFX in phosphate buffer (pH
7.4), that between the serum globulin concentration and
protein binding ratio of LVFX in phosphate buffer (pH
7.4), and that between the serum globulin concentration
and protein binding ratio of LVFX in phosphate buffer
(pH 7.4) containing 3.5 g/dL albumin are shown Figs. 3,
4, and 5, respectively. It was observed that the proteinackgrounds, levofloxacin concentrations, and protein binding
BST (h) SP (g/dL) SA (g/dL) SG (g/dL) LVFX (mg/L) PBR (%)
Just before
HD
6.9 3.9 3.0 4.0 30.9
Just before
HD
6.0 3.6 – 3.9 34.5
Non-HD days 5.0 2.8 2.2 7.6 29.6
Just before
HD
6.4 3.2 3.1 1.9 20.0
Just before
HD
6.5 2.7 3.6 7.3 23.7
Non-HD days 6.4 3.9 2.5 6.5 36.8
6.2 3.4 2.9 5.2 29.3
0.7 0.5 0.5 2.3 6.4
R blood flow rate, TT treatment time, BST blood sampling time after
lin, LVFX serum levofloxacin concentration, PBR protein binding ratio,
Table 3 Non-hemodialysis patients’ demographic profiles, backgrounds, levofloxacin concentrations, and protein binding ratios
Patient no. Age (years) Sex BW (kg) Scr (mg/dL) BST (h) SP (g/dL) SA (g/dL) LVFX (mg/L) PBR (%)
1 59 Female 63.8 0.9 Just before administration 6.6 3.7 4.8 38.8
2 95 Female 35.0 0.7 Just before administration 6.2 2.9 7.7 31.6
3 88 Female 33.3 0.4 Just before administration 6.3 3.4 3.1 37.5
4 87 Female 32.8 0.4 Just before administration 6.8 3.0 1.2 27.7
5 72 Male 43.9 1.0 12 h 5.9 2.6 5.7 24.8
6 86 Female 57.2 1.0 12 h 5.9 3.3 7.4 27.0
7 79 Female 45.7 0.5 Just before administration 6.7 2.8 1.6 31.2
Average 80.9 – 44.5 0.7 – 6.3 3.1 4.5 31.2
SD 12.1 – 12.2 0.3 – 0.4 0.4 2.6 5.3
SD standard deviation, BW body weight, Scr serum creatinine, BST blood sampling time after administration of levofloxacin, SP serum protein, SA serum albumin,
LVFX serum levofloxacin concentration, PBR protein binding ratio
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bumin (r = 0.82, p = 0.09) and globulin (r = 0.93, p = 0.02)
concentrations. However, the protein binding ratio did
not increase with an increase in the serum globulin con-
centration when the buffer also contained 3.5 g/dL albu-
min (r = 0.40, p = 0.43).
Discussion
The protein binding ratios of fluoroquinolones are
known to affect antimicrobial activity in vitro [8–10].
Protein binding is associated with the presence of
uremic toxins [11], among other factors. Thus, in HD
patients, it is possible that the protein binding ratio of
LVFX may fluctuate greatly, thereby affecting antimicro-
bial activity. However, to date, little data is available
regarding the protein binding ratio of LVFX in HD
patients.
Our findings showed that the protein binding ratios of
LVFX were 31.2 and 29.3 % in non-HD and HD patients,
respectively, and that the ratio did not fluctuate signifi-
cantly in HD patients. A possible reason why this ratio
did not fluctuate in HD patients is that LVFX does notFig. 1 Relationship between serum albumin concentration and
protein binding ratio of LVFX in HD and non-HD patients. A statistically
significant (p = 0.03) correlation (r = 0.60) was observed between the
serum albumin concentration and protein binding ratio. black circle HD
patients, white circle non-HD patientsshow very high binding to serum proteins (approxi-
mately 24–38 %) [1] compared with other drugs [11]
(e.g., fosphenytoin 93–98 %). Therefore, the protein
binding ratio of LVFX was found to be similar in HD
and non-HD patients, in agreement with a previous
study [1]. Thus, the protein binding ratio of LVFX is not
associated with the presence of uremic toxins, and the
protein binding ratio holds little clinical relevance for
LVFX therapy in HD patients.
As shown in Fig. 1, a statistically significant correlation
was observed between the serum albumin concentration
and the protein binding ratio in HD and non-HD
patients. However, such a correlation was not observed
between the serum LVFX concentration and protein
binding ratio in vitro (Fig. 2) or in vivo. Therefore, we
considered that the protein binding ratio of LVFX was
primarily affected by the serum albumin concentration,
as reported by Bergogne-Bérézin [7]. Four patients re-
ceived medications with known interactions with LVFX.
Fluoroquinolones are known to interact with drugs con-
taining calcium [12], iron [13], and lanthanum [14] via
chelation interactions; they are also known to interact
with sevelamer [15], manifesting as decreased oral bio-
availability. It is unclear whether these drugs affectedFig. 2 Relationship between serum concentration and protein
binding ratio of LVFX in human serum (in vitro). Mean ± standard
deviation of three experiments
Fig. 3 Relationship between serum albumin concentration and
protein binding ratio of LVFX in phosphate buffer (pH 7.4). Mean ±
standard deviation of three experiments
Fig. 5 Relationship between serum globulin concentration and
protein binding ratio of LVFX in phosphate buffer (pH 7.4)
containing 3.5 g/dL albumin. Mean ± standard deviation of
three experiments
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ered that the protein binding ratio of LVFX had a minimal
effect on the patients who received such medications be-
cause the protein binding ratio was not associated with
serum LVFX concentrations.
As shown in Figs. 3, 4, and 5, LVFX was bound to not
only albumin but also globulin. Moreover, the protein
binding ratio of LVFX increased with increased concen-
trations of albumin as well as globulin. No studies have
reported that LVFX and other fluoroquinolones show
protein binding to serum globulin. However, the protein
binding ratio did not increase with increased serum
globulin concentrations in the presence of 3.5 g/dL albu-
min. We therefore considered that the globulin binding
ratio had a minimal effect on the protein binding ratio
since the globulin binding ratio is lower than the albu-
min binding ratio. These results suggested that the pro-
tein binding ratio of LVFX was minimally affected by
serum globulin concentrations. However, if patients had
severe hypoalbuminemia, the protein binding ratio may
be affected by serum globulin levels.
Our study has certain limitations. These include the
small sample size, few female patients among the HD
patients, and body weight that tended to be higher inFig. 4 Relationship between serum globulin concentration and
protein binding ratio of LVFX in phosphate buffer (pH 7.4). Mean ±
standard deviation of three experimentsthe HD patient group compared with the non-HD
patient group. In addition, the protein binding ratio is
reportedly affected by the pH [7], but we did not meas-
ure the serum pH. Moreover, we did not evaluate the
effect of hemodialysis on the protein binding ratio and
severe hypoalbuminemia.
Conclusions
Overall, our results indicated no differences in the pro-
tein binding ratio of LVFX between non-HD and HD
patients. Moreover, LVFX showed binding to both albu-
min and globulin; however, the protein binding ratio of
LVFX was mainly affected by serum albumin concentra-
tions. Thus, the protein binding ratio of LVFX appears
to have little clinical relevance, and we consider that
it is not necessary to monitor this parameter for
LVFX therapy in HD patients.
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